Etomoxir - CAS 124083-20-1
Catalog number: 124083-20-1
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C17H23ClO4
Molecular Weight:
326.82
COA:
Inquire
Targets:
DGAT
Description:
An inhibitor of carnitine palmitoyltransferase A (CPT1), which is required for the oexidation of long-chain acyl CoA esters. A strong inhibitor of mitochondrial CPT1 and is a candidate as an anti-diabetic drug.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
Etomoxir
MSDS:
Inquire
1.4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8+ T cell proliferation.
Choi BK1, Lee DY1,2, Lee DG1, Kim YH3, Kim SH1, Oh HS1, Han C1, Kwon BS1,4,5. Cell Mol Immunol. 2016 Mar 14. doi: 10.1038/cmi.2016.02. [Epub ahead of print]
4-1BB (CD137) is a strong enhancer of the proliferation of CD8+ T cells. Since these cells require increased production of energy and biomass to support their proliferation, we hypothesized that 4-1BB signaling activated glucose and fatty acid metabolism. We found that treatment with agonistic anti-4-1BB mAb promoted the proliferation of CD8+ T cells in vitro, increasing their size and granularity. Studies with a glycolysis inhibitor and a fatty acid oxidation inhibitor revealed that CD8+ T cell proliferation required both glucose and fatty acid metabolism. Anti-4-1BB treatment increased glucose transporter 1 expression and activated the liver kinase B1 (LKB1)-AMP-activated protein kinase (AMPK)-acetyl-CoA carboxylase (ACC) signaling pathway, which may be responsible for activating the metabolism of glucose and fatty acids. We also examined whether blocking glucose or fatty acid metabolism affected cell cycle progression and the anti-apoptotic effect of 4-1BB signaling.
2.Induction of Posttranslational Modifications of Mitochondrial Proteins by ATP Contributes to Negative Regulation of Mitochondrial Function.
Zhang Y1, Zhao Z1, Ke B1, Wan L1,2, Wang H3, Ye J1. PLoS One. 2016 Mar 1;11(3):e0150454. doi: 10.1371/journal.pone.0150454. eCollection 2016.
It is generally accepted that ATP regulates mitochondrial function through the AMPK signaling pathway. However, the AMPK-independent pathway remains largely unknown. In this study, we investigated ATP surplus in the negative regulation of mitochondrial function with a focus on pyruvate dehydrogenase (PDH) phosphorylation and protein acetylation. PDH phosphorylation was induced by a high fat diet in the liver of obese mice, which was associated with ATP elevation. In 1c1c7 hepatoma cells, the phosphorylation was induced by palmitate treatment through induction of ATP production. The phosphorylation was associated with a reduction in mitochondria oxygen consumption after 4 h treatment. The palmitate effect was blocked by etomoxir, which inhibited ATP production through suppression of fatty acid β-oxidation. The PDH phosphorylation was induced by incubation of mitochondrial lysate with ATP in vitro without altering the expression of PDH kinase 2 (PDK2) and 4 (PDK4).
3.Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy.
Stapel B1, Kohlhaas M2, Ricke-Hoch M1, Haghikia A1, Erschow S1, Knuuti J3, Silvola JM3, Roivainen A3, Saraste A3, Nickel AG2, Saar JA2, Sieve I1, Pietzsch S1, Müller M1, Bogeski I4, Kappl R4, Jauhiainen M5, Thackeray JT6, Scherr M7, Bengel FM6, Hagl C8, T Eur Heart J. 2016 Mar 21. pii: ehw086. [Epub ahead of print]
AIMS: The benefit of the β1-adrenergic receptor (β1-AR) agonist dobutamine for treatment of acute heart failure in peripartum cardiomyopathy (PPCM) is controversial. Cardiac STAT3 expression is reduced in PPCM patients. Mice carrying a cardiomyocyte-restricted deletion of STAT3 (CKO) develop PPCM. We hypothesized that STAT3-dependent signalling networks may influence the response to β-AR agonist treatment in PPCM patients and analysed this hypothesis in CKO mice.
4.Stimulation of astrocyte fatty acid oxidation by thyroid hormone is protective against ischemic stroke-induced damage.
Sayre NL1, Sifuentes M2, Holstein D2, Cheng SY3, Zhu X3, Lechleiter JD4. J Cereb Blood Flow Metab. 2016 Feb 12. pii: 0271678X16629153. [Epub ahead of print]
We previously demonstrated that stimulation of astrocyte mitochondrial ATP production via P2Y1 receptor agonists was neuroprotective after cerebral ischemic stroke. Another mechanism that increases ATP production is fatty acid oxidation (FAO). We show that in primary human astrocytes, FAO and ATP production are stimulated by 3,3,5 triiodo-l-thyronine (T3). We tested whether T3-stimulated FAO enhances neuroprotection, and show that T3 increased astrocyte survival after either hydrogen peroxide exposure or oxygen glucose deprivation. T3-mediated ATP production and protection were both eliminated with etomoxir, an inhibitor of FAO. T3-mediated protection in vitro was also dependent on astrocytes expressing HADHA (hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase), which we previously showed was critical for T3-mediated FAO in fibroblasts. Consistent with previous reports, T3-treatment decreased stroke volumes in mice.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related DGAT Products


CAS 956136-95-1 LCQ-908

LCQ-908
(CAS: 956136-95-1)

LCQ-908 is a new generation of diacylglycerol acyltransferase 1 (DGAT1) inhibitor as anti-obesity and anti-diabetic agents. It is now in phase II clinical trial...

CAS 124083-20-1 Etomoxir

Etomoxir
(CAS: 124083-20-1)

An inhibitor of carnitine palmitoyltransferase A (CPT1), which is required for the oexidation of long-chain acyl CoA esters. A strong inhibitor of mitochondrial...

CAS 892489-52-0 AZD 3988

AZD 3988
(CAS: 892489-52-0)

AZD 3988 is a selective and potent diacylglycerol O-acyltransferase (DGAT) enzyme inhibitor with IC50 value of 0.6 nM. It is selective for DGAT-1 over DGAT-2, c...

CAS 1031336-60-3 ABT-046

ABT-046
(CAS: 1031336-60-3)

ABT-046 is a potent, selective, and orally bioavailable Diacylglycerol acyltransferase 1 (DGAT-1 ) inhibitor (IC50=8 nM).

CAS 1962931-71-0 JNJ DGAT2-A

JNJ DGAT2-A
(CAS: 1962931-71-0)

JNJ DGAT2-A has been found to be a DGAT2 inhibitor (IC50 = 140 nM) and also a useful intermediate.

PF-06424439
(CAS: 1469284-78-3)

PF-06424439, a imidazo-pyridin derivative, has been found to be a selective DGAT2 inhibitor that could be probably effective against dyslipidemic rodent in anim...

CAS 942999-61-3 DGAT-1 inhibitor 2

DGAT-1 inhibitor 2
(CAS: 942999-61-3)

DGAT-1 inhibitor 2 is an effective inhibitor of DGAT-1, which is one of two known DGAT enzymes that catalyze the final step in triglyceride synthesis. It is a p...

CAS 1449779-49-0 DGAT1-IN-1

DGAT1-IN-1
(CAS: 1449779-49-0)

Imidazopyridine and imidazothiazole compounds as inhibitors of diacylglycerol o-acyltransferase type 1 enzyme and their preparation.

CAS 959122-11-3 A922500

A922500
(CAS: 959122-11-3)

A922500 is an inhibitor for human and mouse DGAT-1 with IC50 of 7 nM and 24 nM, respectively, good selectivity over related acyltransferases, hERG, and a panel ...

CAS 701232-20-4 T863

T863
(CAS: 701232-20-4)

T-863 is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that interacts with the acyl-CoA binding site of DGA...

CAS 1109276-89-2 PF-04620110

PF-04620110
(CAS: 1109276-89-2)

PF-04620110 is an orally active, selective and potent diglyceride acyltransferase-1 (DGAT1) inhibitor with IC50 of 19 nM.

CAS 828934-41-4 (R)-((addition))-Etomoxir sodium salt

(R)-((addition))-Etomoxir sodium salt
(CAS: 828934-41-4)

(R)-((addition))-Etomoxir sodium salt is a potent inhibitor of carnitine palmitoyltransferase I (CPT1), which inhibits β-oxidation in mitochondria. It has shown...

CAS 1166827-44-6 AZD7687

AZD7687
(CAS: 1166827-44-6)

AZD7687 is a potent and selective DGAT1 inhibitor with an IC50 value of 80 nM (hDGAT1).

Chemical Structure

CAS 124083-20-1 Etomoxir

Quick Inquiry

Verification code

Featured Items